Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain

Inclusion Criteria:

• Patients of legal age with stage III, metastatic, or unresectable melanoma at firstdiagnosis after January 8, 2018. First diagnosis is understood as: a. Disease onsetas metastatic or unresectable disease; b. First metastatic or unresectable relapsein the pre-established dates (after January 8, 2018) in a patient with previouslocalised melanoma and completely resected on dates before the pre-inclusion period.

• Signing the Informed Consent Form (ICF).

• A patient may have received the first or subsequent treatments for metastatic orunresectable disease in a hospital other than the centre where the ICF was signed,as long as the patient meets the inclusion criteria 1.

• A patient can only sign one ICF (cannot sign an ICF in two different centres).

• If a patient signs the ICF in a centre during the first-line therapy and then goesto another centre with consideration for the following lines: If the centre isassociated with the GEM-1801 study, researchers will do their best to update thefollowing lines and the patient status, introducing the new information in thecentre where the ICF was initially signed. This information will be provided by thepatient before contacting the principal investigator and always with prior consentof the patient, who will have previously provided the consent to contact bytelephone for this purpose. If this second (or subsequent) centre is not associatedwith the GEM- 1801 study, this will be considered loss of follow-up, unless thepatient returns to the GEM-1801 start centre, wherein the reporting physicians willdo their best to update the information from other centres, always with priorpatient consent, who will have previously signed the ICF; c) A patient card with theassigned code will be delivered.

Exclusion Criteria:

• Any patient not complying with inclusion criteria.